Company / Cash & Equivalents
RIGEL PHARMACEUTICALS INC Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$40.6M
FY2025
5-year range
$18.9M / $56.7M
FY2021-FY2025
Trend
-28.5%
vs FY2024
Sector context
#190 of 207
Health Care
What the data says
Among 207 Health Care companies, RIGEL PHARMACEUTICALS INC is in the bottom 8% for cash & equivalents. Cash & Equivalents has fluctuated over the past 10 years, ranging from $18M in FY2018 to $57M in FY2024.
Based on SEC 10-K filings.
$41M in FY2025 with a 5-year CAGR of +6.0%.
Improved from $33M to $41M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +18.4%
- 5-Year CAGR
- +6.0%
- 10-Year CAGR
- -
Sector benchmark
Bottom 8% in Health CareTop 92% of 207This company $40.6M Sector average $669.5M
▼
-93.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +6.0%, indicating consistent growth.
- In FY2025, cash & equivalents decreased 28.5% year-over-year.
- Ranks #190 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 1.19 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $40.6M | -28.5% |
| FY2024 | $56.7M | +73.1% |
| FY2023 | $32.8M | +34.0% |
| FY2022 | $24.5M | +29.5% |
| FY2021 | $18.9M | -37.8% |
| FY2020 | $30.4M | +34.9% |
| FY2019 | $22.5M | +27.7% |
| FY2018 | $17.6M | -54.0% |
| FY2017 | $38.3M | +117.2% |
| FY2016 | $17.6M | -59.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026